Osteoporosis is a common disease in postmenopausal women and older men. Bisphosphonates, the first-line drug for the osteoporosis, have a residual effect and can continue to exert a persistent inhibitory effect on osteoclast function after therapy is stopped. Although bisphosphonates are proven to be generally safe, concerns have emerged about potential adverse effects related to long-term use, such as atypical femoral fractures and osteonecrosis of the jaw. The purpose of drug holiday is to reduce the use of bisphosphonates with the guarantee of good bone mass and bone mineral density for osteoporosis patients, so to minimize the possible adverse effects of long-term use. During the drug holiday, relevant bone indexes should be properly monitored, and the therapy should be restarted immediately if there is a significant decrease in bone mineral density or new fractures.